Compare Sibanye Stillwater Ltd (SBSW) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sibanye Stillwater Ltd vs BIO-TECHNE Corp — how do they compare? Sibanye Stillwater Ltd trades at $10 (market cap $6.88B), while BIO-TECHNE Corp trades at $72.46 (market cap $11.36B). The key difference: BIO-TECHNE Corp is the larger of the two by market cap, and Sibanye Stillwater Ltd pays the higher dividend (8.17%). Which is the better fit depends on your goals — on Pluang, investors hold Sibanye Stillwater Ltd for 51 Days and BIO-TECHNE Corp for 63 Days on average.
| SBSW | TECH | |
|---|---|---|
Market Cap | $6.88B | $11.36B |
Volume | 4,474,536 | 5,390,331 |
Sector | Basic Materials | Health |
52-Week High | $21.12 | $72.61 |
52-Week Low | $8.00 | $43.31 |
Typical Hold Time | 51 Days | 63 Days |
Enterprise Value | $7.78B | $11.39B |
Dividend Yield | 8.17% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SBSW trades at $9.68, down 3.3% today, amid a bearish technical outlook. The stock shows mixed earnings with a recent Q2 2026 beat but a Q4 2025 miss. Fundamentals reflect strong revenue growth projected to $164.9B in 2026 and attractive valuation ratios, including a P/E of 8.12 and EV/EBITDA of 4.09, though net income was negative in 2025. Cash flow trends improved significantly in 2025, turning net positive. Analyst sentiment is moderately bullish with a $14.25 consensus target.
The outlook hinges on execution of its growth roadmap and commodity price stability. Upside potential exists from operational momentum and disciplined capital allocation, but risks include debt levels, volatile earnings, and macroeconomic pressures on mining sectors. The stock presents a value opportunity if profitability rebounds as projected.
Bio-Techne (TECH) trades at $72.47, down 0.08% on the day, near its 52-week high of $72.70 (Defense World, 2026-09-28). The stock shows a bullish technical trend with strong moving average signals. Recent shareholder approval of the acquisition by Merck KGaA at $73.00 per share (PRNewsWire, 2026-09-23) is a key catalyst. Q2 2026 earnings beat expectations with EPS of $0.52 versus $0.519 expected, though net income margin has declined from 25.09% in 2023 to 14.96% in 2026.
The pending acquisition offers a near-term upside to the current price, but high valuation ratios (P/E of 62.46, P/S of 9.36) pose a risk if the deal faces regulatory hurdles. Analyst consensus is mixed with 46% Buy and 54% Hold ratings. The stock presents a favorable risk-reward for investors seeking a takeover arbitrage opportunity, with the primary risk being deal failure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sibanye Stillwater Ltd
Sibanye Stillwater Ltd is a South Africa-focused mining company. The Group currently owns and operates five underground and surface gold operations in South Africa: the Cooke, DRDGOLD, Driefontein, and Kloof operations in the West Witwatersrand region, and the Beatrix Operation in the southern Free State province. In addition to mining, the company owns and manages extraction and processing facilities at its operations, where gold-bearing ore is treated and beneficiated to produce gold dore. The gold dore is further refined at Rand Refinery into gold bars with a purity of at least 99.5% and is then sold on international markets. Sibanye holds a 44% interest in Rand Refinery, global refiners of gold, and the largest in Africa. Rand Refinery markets gold to customers around the world.
Read more on SBSW →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
